Litigation Update

Hipgnosis Songs Fund Limited
19 February 2024
 

LEI: 213800XJIPNDVKXMOC11

19 February 2024

 

Hipgnosis Songs Fund Limited ("Hipgnosis" or the "Company")

Litigation Update

The Company announced on 5 February 2024 that it is seeking to secure an indemnity from Merck Mercuriadis and Hipgnosis Songs Management Limited (the "Investment Adviser"), which is majority owned by funds managed and/or advised by Blackstone, further to High Court proceedings being issued and served upon Mr Mercuriadis, the Investment Adviser and the Company.

The Investment Adviser, which was founded by Mr Mercuriadis and where Mr Mercuriadis is a director, has refused to indemnify the Company against liabilities which may arise from Mr Mercuriadis' alleged misconduct.

The Company is concerned, having been assured by Mr Mercuriadis and the Investment Adviser that these claims are without merit and that they intend to vigorously defend them, that the request for an indemnity was refused. The Company is not insured as to the costs of this claim.

The Company now intends to bring a Part 20 Claim in the High Court against the Investment Adviser in which it will seek a full indemnity.

For further information please contact:
Hipgnosis Songs Fund

Robert Naylor

Via Singer Capital Markets


  

+44 (0) 20 7496 3000

 

 

Singer Capital Markets - Corporate Broker

James Moat / Alaina Wong / Angus Campbell (Corporate Finance)

Alan Geeves / James Waterlow / Sam Greatrex (Sales) 


+44 (0) 20 7496 3000

Headland Consultancy - Financial PR

Susanna Voyle / Charlie Twigg

 


+44 (0) 20 3805 4822

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings